For the secondary end points , the least-square mean absolute differences between groups all favored eliglustat , with a @-g / dL increase in hemoglobin level ( @ % CI , @-@ @ g/dL ; P < @ ) , @ % decrease in liver volume ( @ % CI , -@ % to -@ % ; P = @ ) , and @ % increase in platelet count ( @ % CI , @ % -@ % ; P < @ ) .